Global Respiratory Distress Syndrome Market Growth (Status and Outlook) 2025-2031

Global Respiratory Distress Syndrome Market Growth (Status and Outlook) 2025-2031

The global Respiratory Distress Syndrome market size is predicted to grow from US$ 411 million in 2025 to US$ 573 million in 2031; it is expected to grow at a CAGR of 5.7% from 2025 to 2031.

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.

LPI (LP Information)' newest research report, the “Respiratory Distress Syndrome Industry Forecast” looks at past sales and reviews total world Respiratory Distress Syndrome sales in 2024, providing a comprehensive analysis by region and market sector of projected Respiratory Distress Syndrome sales for 2025 through 2031. With Respiratory Distress Syndrome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Respiratory Distress Syndrome industry.

This Insight Report provides a comprehensive analysis of the global Respiratory Distress Syndrome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Respiratory Distress Syndrome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Respiratory Distress Syndrome market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Respiratory Distress Syndrome and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Respiratory Distress Syndrome.

This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Distress Syndrome market by product type, application, key players and key regions and countries.

Segmentation by Type:
Poractant Alfa
Beractant
Calfactant
Others

Segmentation by Application:
Very Preterm Infants
Moderate to Late Preterm Infants
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Chiesi Farmaceutici
CR-Double Crane
ONY Biotech
AbbVie
Yuhan Corporation
JW Pharmaceuticals
Noargen